Acalabrutinib 100mg - αποτελεσματα

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

calquence hard capsules 100mg

astrazeneca singapore pte ltd - acalabrutinib - capsule - acalabrutinib 100mg

calquence

astrazeneca (israel) ltd - acalabrutinib - capsules - acalabrutinib 100 mg - mantle cell lymphomacalquence is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.chronic lymphocytic leukemia or small lymphocytic lymphomacalquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll)or small lymphocytic lymphoma (sll).

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

calquence film-coated tablet 100mg

astrazeneca singapore pte ltd - acalabrutinib maleate eqv acalabrutinib - tablet, film coated - acalabrutinib maleate eqv acalabrutinib 100mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

calquence 100mg capsules

imported (united states) - acalabrutinib - capsule - 100mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

calquence 100mg capsules

astrazeneca uk ltd - acalabrutinib - capsule - 100mg

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll).calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.